Home・Aktien・Beam Therapeutics Inc

Beam Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

26.71 -0.3

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

26.58

Max

27.2

Schlüsselkennzahlen
By Trading Economics
Einkommen	-28M -123M
Verkäufe	-31M 490K
EPS	-1.18
Gewinnspanne	-25,036.327
Angestellte	540
EBITDA	-36M -125M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+95.53% upside

Dividenden
By Acuity
Nächstes Ergebnis	2. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	152M 2.8B
Vorheriger Eröffnungskurs	27.01
Vorheriger Schlusskurs	26.71

Beam Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Aug. 2026, 20:06 UTC

Beam Therapeutics Inc. shares are lower today, continuing a trend of declines since Tuesday's close amid broader market uncertainties and lower U.S. Treasury yields.

11. Aug. 2026, 23:06 UTC

Beam Therapeutics shares are higher in after-market trading, following a session peak. No specific news was identified to explain the price movement.

5. Aug. 2026, 19:52 UTC

Correlated Moves

Beam Therapeutics Inc is trading lower as broader market sentiment weakens. The decline follows disappointing ADP employment data, which missed expectations significantly.

4. Aug. 2026, 23:06 UTC

Beam Therapeutics Inc. shares are lower in after-market hours, following a session low shortly after the open, despite three consecutive higher daily closes.

3. Aug. 2026, 19:16 UTC

Correlated Moves

News

Beam Therapeutics is rising amid a broader market rally, with a market cap of $2.64 billion and $1.2 billion in liquidity to support operations.

31. Juli 2026, 19:16 UTC

Correlated Moves

Beam Therapeutics shares are lower, reflecting a decline in first-quarter results and broader sector weakness. The stock remains near the lower end of its one-month range.

30. Juli 2026, 23:06 UTC

Beam Therapeutics Inc shares are higher in after-hours trading, advancing since Thursday's close, despite remaining below the 20-day moving average.

29. Juli 2026, 22:51 UTC

Beam Therapeutics shares are lower in after-market hours following a volatile session, amid broader market uncertainty after the Federal Reserve's interest rate decision.

28. Juli 2026, 23:51 UTC

Beam Therapeutics Inc shares are lower in after-market trading, experiencing unusual volatility amid broader market declines and positioned below its 20-day moving average.

27. Juli 2026, 23:06 UTC

Beam Therapeutics Inc shares are higher in after-market hours, despite a broader decline in trading. No specific news was identified to explain the increase.

24. Juli 2026, 19:26 UTC

Event

Correlated Moves

Beam Therapeutics is declining today, reflecting broader market trends, with the Russell 2000 Index down. The stock remains below its 20-day moving average.

23. Juli 2026, 09:51 UTC

News

Beam Therapeutics is higher in pre-market trading, driven by significant upcoming clinical milestones, including the global BEAM-302 trial and an FDA application for risto-cel.

22. Juli 2026, 23:46 UTC

Beam Therapeutics shares higher in after-market trading, advancing since Wednesday's close. The stock remains below its 20-day moving average amid broader market influences.

21. Juli 2026, 18:06 UTC

Correlated Moves

Beam Therapeutics shares are higher today, reflecting positive sentiment in small-cap stocks amid anticipation of upcoming earnings results from major companies.

20. Juli 2026, 23:56 UTC

Beam Therapeutics Inc is higher in after-market trading, showing notable strength since Monday's close. No specific news was identified to explain the movement.

Peer-Vergleich

Kursveränderung

Beam Therapeutics Inc Prognose

Kursziel

By TipRanks

95.53% Vorteil

12-Monats-Prognose

Durchschnitt 52.5 USD 95.53%

Hoch 80 USD

Tief 26 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Beam Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

Buy

Halten

Sell

Basierend auf 13 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Beam Therapeutics Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.